TR200000786T2 - Vitronektin reseptör antagonisti - Google Patents

Vitronektin reseptör antagonisti

Info

Publication number
TR200000786T2
TR200000786T2 TR2000/00786T TR200000786T TR200000786T2 TR 200000786 T2 TR200000786 T2 TR 200000786T2 TR 2000/00786 T TR2000/00786 T TR 2000/00786T TR 200000786 T TR200000786 T TR 200000786T TR 200000786 T2 TR200000786 T2 TR 200000786T2
Authority
TR
Turkey
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
TR2000/00786T
Other languages
English (en)
Inventor
H. Miller William
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200000786T2 publication Critical patent/TR200000786T2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bir vitronektin reseptörü antagonisti olup osteoporoz tedavisinde yararli olan bir formül (1) bilesimi veya farmasötik olarak kabul edilebilir bir tuzu açiklanmaktadir.
TR2000/00786T 1997-09-24 1998-09-24 Vitronektin reseptör antagonisti TR200000786T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5986797P 1997-09-24 1997-09-24

Publications (1)

Publication Number Publication Date
TR200000786T2 true TR200000786T2 (tr) 2000-08-21

Family

ID=22025805

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00786T TR200000786T2 (tr) 1997-09-24 1998-09-24 Vitronektin reseptör antagonisti

Country Status (13)

Country Link
EP (1) EP1023073A1 (tr)
JP (1) JP2002500162A (tr)
KR (1) KR20010024249A (tr)
CN (1) CN1271284A (tr)
AU (1) AU9578798A (tr)
BR (1) BR9813214A (tr)
CA (1) CA2304000A1 (tr)
HU (1) HUP0003931A2 (tr)
IL (1) IL135188A0 (tr)
NO (1) NO20001515L (tr)
PL (1) PL339414A1 (tr)
TR (1) TR200000786T2 (tr)
WO (1) WO1999015178A1 (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046215A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
RU2316337C2 (ru) 2001-04-24 2008-02-10 Мерк Патент Гмбх КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
US7368566B2 (en) 2003-04-04 2008-05-06 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
DE602005012233D1 (de) 2004-02-02 2009-02-26 Pioneer Hi Bred Int Ap2-domäne-transkriptionsfaktor odp2 (ovule development protein 2) und verwendungsverfahren
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1973569B1 (en) 2006-01-18 2013-05-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
PL2101805T3 (pl) 2007-01-18 2013-04-30 Merck Patent Gmbh Ligandy integryn do stosowania w leczeniu nowotworów
AU2008321770B2 (en) * 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
EP2415474B1 (en) 2009-03-30 2013-08-28 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
WO2010136168A2 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
CN102892888A (zh) 2009-12-30 2013-01-23 先锋国际良种公司 在植物中导入并调节表达基因的方法和组合物
CA2793596A1 (en) 2009-12-30 2011-07-07 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
AU9578798A (en) 1999-04-12
IL135188A0 (en) 2001-05-20
HUP0003931A2 (hu) 2001-10-28
NO20001515D0 (no) 2000-03-23
NO20001515L (no) 2000-03-23
PL339414A1 (en) 2000-12-18
EP1023073A1 (en) 2000-08-02
CA2304000A1 (en) 1999-04-01
JP2002500162A (ja) 2002-01-08
CN1271284A (zh) 2000-10-25
BR9813214A (pt) 2000-08-29
KR20010024249A (ko) 2001-03-26
WO1999015178A1 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
TR200000786T2 (tr) Vitronektin reseptör antagonisti
TR199801253T2 (tr) Vitronektin reseptörü antagonistleri.
MX9805253A (es) Antagonistas del receptor de vitronectina.
BG106585A (en) Kinase inhibitors as therapeutic agents
TR199700844T1 (tr) Pirazolil-Benzoil Türevleri.
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
MX9700041A (es) Antagonistas de receptor de vitronectina.
ATE306261T1 (de) Antithrombosemittel
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
NO20001514L (no) Vitronectin-reseptor-antagonist
TR200000721T2 (tr) Vitronektin reseptör antagonistleri.
TR199902283T2 (tr) Ikame edilmis izokuinolin türevleri ve bunlarin antikonvulsant olarak kullanimi.
ES2182349T3 (es) Procedimiento de orto-metalizacion para la sintesis de 1-(tetrazol-5-il)bencenos sustituidos en la posicion 2.
NO975975L (no) Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
DE60112960D1 (de) Kondensierte pyridoindolderivate
TR200200614T2 (tr) Vitronektin reseptörü antagonistleri
ATE284871T1 (de) Bicyclische vasopressin-agoniste
CA2278057A1 (en) Tachykinin antagonists
FR2796829B1 (fr) Plaque d'osteotomie tibiale
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DK0896822T3 (da) 4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
WO2000007544A3 (en) Vitronectin receptor antagonists